Apricus Biosciences Announces Allowance of a NexACT(R) Technology-Based Patent in Europe for the Manufacture of DDAIP
Apricus Biosciences, Inc.
22.03.2012 12:00
---------------------------------------------------------------------------
SAN DIEGO, 2012-03-22 12:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), announced today that the European Patent Office
('EPO') has issued an official decision to allow the Company's patent
application entitled, 'Method for the Manufacture of Dodecyl
2-(N,N-Dimenthylamino)-Propionate.' The allowed patent application is a
divisional of a Company-owned European patent issued in 2000 entitled
'Crystalline Salts of Dodecyl 2-(N,N-Dimenthylamino)-Propionate' that protects
the DDAIP.HCl compound and method of manufacture.
The recently allowed divisional application covers the transesterification
approach to synthesizing DDAIP (the main chemical penetration enhancing
compound used in the Company's NexACT(r) technology) and results in a product
containing relatively lower levels of by-products and unreacted reactants,
which are undesirable and difficult to remove by conventional methods. This may
result in significant cost savings on the finished product. This patent, when
issued, will provide European patent protection to March 2020 and will be the
16th patent granted for this technology worldwide, with three applications
pending in this patent family.
Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus
Bio, commented, 'We are very pleased to receive this additional important
patent in Europe for the manufacture of a core component of our NexACT(r)
technology. When issued, this patent will allow us to further protect the
manufacture of DDAIP as well as the manufacture of the crystalline form of
DDAIP. DDAIP in these two forms (one a liquid and the other a salt) allow for
different pharmaceutical applications.'
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based revenue-generating hybrid specialty
pharmaceutical company, with commercial products and a broad pipeline across
numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial
products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc.
subsidiaries and through out-licensing in certain territories of its product
pipeline and NexACT(r) technology.
Apricus Bio's current NexACT(r) pipeline includes Vitaros(r), approved in Canada
for the treatment of erectile dysfunction, as well as compounds in development
from pre-clinical through pre-registration currently focused on Sexual
Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes
and Consumer Healthcare.
Apricus Bio currently markets Totect(r) (dexrazoxane HCl), the only drug approved
in the US for the treatment of anthracycline extravasation. The Company also
plans to market in the U.S. or certain other countries the following products:
(a) Granisol(r) (granisetron HCI) oral solution, the only FDA-approved, oral,
ready-to-use liquid solution of granisetron, (b) Aquoral(tm), an FDA-cleared,
prescription-only spray for the treatment of Xerostomia (the medical term for
dry mouth due to a lack of saliva) and (c) NitroMist(r) (nitroglycerin sublingual
spray), an FDA-approved nitrate vasodilator indicated for acute relief of an
attack or acute prophylaxis of angina pectoris (chest pain) due to coronary
artery disease (narrowing of the blood vessels that supply blood to the heart).
The Company also expects to develop and/or acquire and then bring to market
additional pharmaceutical products in areas of care that will benefit patient
needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its products and product candidates receive patent
protection and be approved by relevant regulatory authorities, to successfully
commercialize such products as Totect(r), Granisol(r), Aquoral(tm) and NitroMist(tm) and
Vitaros(r) for erectile dysfunction and NexACT(r) product candidates and drug
delivery technology and to achieve its development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
22.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Apricus Biosciences, Inc.
22.03.2012 12:00
---------------------------------------------------------------------------
SAN DIEGO, 2012-03-22 12:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), announced today that the European Patent Office
('EPO') has issued an official decision to allow the Company's patent
application entitled, 'Method for the Manufacture of Dodecyl
2-(N,N-Dimenthylamino)-Propionate.' The allowed patent application is a
divisional of a Company-owned European patent issued in 2000 entitled
'Crystalline Salts of Dodecyl 2-(N,N-Dimenthylamino)-Propionate' that protects
the DDAIP.HCl compound and method of manufacture.
The recently allowed divisional application covers the transesterification
approach to synthesizing DDAIP (the main chemical penetration enhancing
compound used in the Company's NexACT(r) technology) and results in a product
containing relatively lower levels of by-products and unreacted reactants,
which are undesirable and difficult to remove by conventional methods. This may
result in significant cost savings on the finished product. This patent, when
issued, will provide European patent protection to March 2020 and will be the
16th patent granted for this technology worldwide, with three applications
pending in this patent family.
Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus
Bio, commented, 'We are very pleased to receive this additional important
patent in Europe for the manufacture of a core component of our NexACT(r)
technology. When issued, this patent will allow us to further protect the
manufacture of DDAIP as well as the manufacture of the crystalline form of
DDAIP. DDAIP in these two forms (one a liquid and the other a salt) allow for
different pharmaceutical applications.'
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based revenue-generating hybrid specialty
pharmaceutical company, with commercial products and a broad pipeline across
numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial
products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc.
subsidiaries and through out-licensing in certain territories of its product
pipeline and NexACT(r) technology.
Apricus Bio's current NexACT(r) pipeline includes Vitaros(r), approved in Canada
for the treatment of erectile dysfunction, as well as compounds in development
from pre-clinical through pre-registration currently focused on Sexual
Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes
and Consumer Healthcare.
Apricus Bio currently markets Totect(r) (dexrazoxane HCl), the only drug approved
in the US for the treatment of anthracycline extravasation. The Company also
plans to market in the U.S. or certain other countries the following products:
(a) Granisol(r) (granisetron HCI) oral solution, the only FDA-approved, oral,
ready-to-use liquid solution of granisetron, (b) Aquoral(tm), an FDA-cleared,
prescription-only spray for the treatment of Xerostomia (the medical term for
dry mouth due to a lack of saliva) and (c) NitroMist(r) (nitroglycerin sublingual
spray), an FDA-approved nitrate vasodilator indicated for acute relief of an
attack or acute prophylaxis of angina pectoris (chest pain) due to coronary
artery disease (narrowing of the blood vessels that supply blood to the heart).
The Company also expects to develop and/or acquire and then bring to market
additional pharmaceutical products in areas of care that will benefit patient
needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its products and product candidates receive patent
protection and be approved by relevant regulatory authorities, to successfully
commercialize such products as Totect(r), Granisol(r), Aquoral(tm) and NitroMist(tm) and
Vitaros(r) for erectile dysfunction and NexACT(r) product candidates and drug
delivery technology and to achieve its development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
22.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------